1. Discovery of highly potent human glutaminyl cyclase (QC) inhibitors as anti-Alzheimer's agents by the combination of pharmacophore-based and structure-based design.
- Author
-
Van Manh N, Hoang VH, Ngo VTH, Ann J, Jang TH, Ha JH, Song JY, Ha HJ, Kim H, Kim YH, Lee J, and Lee J
- Subjects
- Alzheimer Disease metabolism, Aminoacyltransferases metabolism, Amyloid beta-Peptides antagonists & inhibitors, Amyloid beta-Peptides metabolism, Animals, Benzimidazoles chemical synthesis, Benzimidazoles chemistry, Cyclopentanes chemical synthesis, Cyclopentanes chemistry, Dose-Response Relationship, Drug, Drug Discovery, Enzyme Inhibitors chemical synthesis, Enzyme Inhibitors chemistry, Humans, Male, Mice, Mice, Inbred ICR, Molecular Structure, Neuroprotective Agents chemical synthesis, Neuroprotective Agents chemistry, Structure-Activity Relationship, Alzheimer Disease drug therapy, Aminoacyltransferases antagonists & inhibitors, Benzimidazoles pharmacology, Cyclopentanes pharmacology, Enzyme Inhibitors pharmacology, Neuroprotective Agents pharmacology
- Abstract
The inhibition of glutaminyl cyclase (QC) may provide a promising strategy for the treatment of early Alzheimer's disease (AD) by reducing the amount of the toxic pyroform of β-amyloid (Aβ
Ν3pE ) in the brains of AD patients. In this work, we identified potent QC inhibitors with subnanomolar IC50 values that were up to 290-fold higher than that of PQ912, which is currently being tested in Phase II clinical trials. Among the tested compounds, the cyclopentylmethyl derivative (214) exhibited the most potent in vitro activity (IC50 = 0.1 nM), while benzimidazole (227) showed the most promising in vivo efficacy, selectivity and druggable profile. 227 significantly reduced the concentration of pyroform Aβ and total Aβ in the brain of an AD animal model and improved the alternation behavior of mice during Y-maze tests. The crystal structure of human QC (hQC) in complex with 214 indicated tight binding at the active site, supporting that the specific inhibition of QC results in potent in vitro and in vivo activity. Considering the recent clinical success of donanemab, which targets AβΝ3pE , small molecule-based QC inhibitors may also provide potential therapeutic options for early-stage AD treatment., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2021 Elsevier Masson SAS. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF